Abstract:
The present invention relates to compounds useful as inhibitors of Aurora protein kinase of the following formula: or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
Abstract:
The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
Abstract:
A system and method is provided for synthesizing audio-visual content in a video image processor. A content synthesis application processor extracts audio features and video features from audio-visual input signals that represent a speaker who is speaking. The processor uses the extracted visual features to create a computer generated animated version of the face of the speaker. The processor synchronizes facial movements of the animated version of the face of the speaker with a plurality of audio logical units such as phonemes that represent the speaker's speech. In this manner the processor synthesizes an audio-visual representation of the speaker's face that is properly synchronized with the speaker's speech.
Abstract:
This invention describes novel pyrazole compounds of formula IIIa: wherein R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx, Ry, R2, and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Abstract:
The present invention provides a facile process for the preparation of tri- and tetra-substituted pyrimidines. The process is useful for preparing inhibitors of protein kinases, especially Aurora kinase. These inhibitors are useful for treating or lessening the severity of Aurora-mediated diseases or conditions.
Abstract:
This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3 is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 is a hydrogen or C1-6 alkyl or R3 and R4 taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R5 are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1β secretion.
Abstract:
A system and method of adding hyperlinked information to a television broadcast. The broadcast material is analyzed and one or more regions within a frame are identified. Additional information can be associated with a region, and can be transmitted in encoded form, using timing information to identify the frame with which the information is associated. The system comprising a video source and an encoder that produces a transport stream in communication with the video source, an annotation source, a data packet stream generator that produces encoded annotation data packets in communication with the annotation source and the encoder, and a multiplexer system in communication with the encoder and the data packet stream generator. The encoder provides timestamp information to the data packet stream generator and the data packet stream generator synchronizes annotation data from the annotation source with a video signal from the video source in response to the timestamp information. The multiplexer generates a digital broadcast signal that includes an augmented transport stream from the transport stream and the encoded data packets. A receiver displays the annotation information associated with the video signal in response to a viewer request on a frame by frame basis. A viewer can respond interactively to the material, including performing commercial transactions, by using a backchannel that is provided for interactive communication.
Abstract:
This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 is a hydrogen or C1-6 alkyl or R3 and R4 taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R5 are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1β secretion.
Abstract translation:本发明提供了式I的半胱天冬酶抑制剂:其中Z是氧或硫; R 1是氢,-CHN 2,R 2,CH 2 OR,CH 2 SR或-CH 2 Y> Y; R 3和R 4之间代表单键或双键; Y是电负离子团; R 2是CO 2 H,CH 2 CO 2 H,或它们的酯,酰胺或等体醇; R 3是能够适应半胱天冬酶的S2亚位点的基团; R 4是氢或C 1-6烷基或R 3和R 4合在一起形成环 ; 环A和环B各自是杂环,R和R 5如说明书中所述。 这些化合物是凋亡和IL-1β分泌的有效抑制剂。
Abstract:
The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
Abstract:
A process for the production of ethyl acetate by reacting ethylene with acetic acid and water in the presence of a heteropolyacid catalyst in which the concentrations of reactants in the feed stream to the reactor are such that the mole ratio of ethylene to acetic acid lies in the range 6.0 to 12.2, the mole ratio of ethylene to water lies in the range 8.0 to 17.0 and the mole ratio of acetic acid to water lies in the range 1.25 to 1.40. It has been found that by careful control of the relative concentration of the reactants and of the process operating conditions the relative amounts of methyl ethyl ketone (MEK, 2-butanone) coproduced with the desired ethyl acetate can be reduced and the catalyst life can thereby be extended.